Aligos Therapeutics, Inc. a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, announced that it has expanded its ongoing collaboration agreement with Merck, known as MSD outside of the United States and Canada, to discover and develop oligonucleotide therapies for non-alcoholic steatohepatitis (NASH).